)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CANbridge Pharmaceuticals
CANbridge Pharmaceuticals (1228) investor relations material
CANbridge Pharmaceuticals H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Achieved 25.6% year-over-year revenue growth to RMB27.9 million, driven by increased sales of Hunterase and Livmarli, and expanded approvals and insurance coverage in China and Taiwan.
Raised HK$200 million via strategic investment from WuXi Biologics, strengthening financial position and R&D funding.
Transitioned to an exclusive CSO model with Baheal Zhihe for commercialization in China, Hong Kong, and Macau.
Advanced global expansion, including Gaurunning’s entry into North Africa and new pipeline developments such as next-generation gene therapy and CNS-targeted ERT assets.
Achieved significant progress in patient identification and insurance coverage for rare disease therapies.
Financial highlights
Revenue rose to RMB27.9 million from RMB22.2 million year-over-year, mainly from Hunterase and Livmarli.
Gross profit increased to RMB18.7 million, with gross margin at 66.8% (down from 69.3%).
Other income and gains dropped sharply to RMB11.3 million from RMB104.1 million, due to a one-time US lease termination gain in the prior year.
Selling and distribution expenses rose 36.3% to RMB30.9 million, reflecting new product launches and CSO transition.
Administrative expenses increased 40.3% to RMB23.3 million, mainly from share-based payments and financing fees.
R&D expenses decreased 30.5% to RMB12.5 million, reflecting lower costs after clinical trial completions.
Net loss for the period was RMB37.1 million, compared to a profit of RMB59.2 million in the prior year, mainly due to the absence of one-off gains; adjusted loss narrowed to RMB28.2 million.
Outlook and guidance
Plans to expand commercial sales of Hunterase, Livmarli, and Gaurunning in China and overseas, leveraging CSO partnership and new insurance coverage in Taiwan.
Continued investment in R&D, global business development, and next-generation gene therapy platforms.
Aims to accelerate value creation and deliver sustainable returns, supported by favorable policy and industry trends.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CANbridge Pharmaceuticals
- Sales grew and losses narrowed, but liquidity pressure and going-concern uncertainty remain.1228
H2 2023 - Gross margin rose to 74.7% as adjusted loss narrowed, but going concern risk persists.1228H2 2025
- Revenue and cash fell sharply amid higher losses, but key drug launches and approvals advanced.1228H2 2024
- Profit driven by one-time gains amid revenue drop; liquidity risk persists despite new capital.1228H1 2025
- Revenue up 4% but losses widened on higher R&D; cash fell, raising going concern risks.1228H1 2024
Next CANbridge Pharmaceuticals earnings date
H2 202629 Mar, 2027
CANbridge Pharmaceuticals
Next CANbridge Pharmaceuticals earnings date
H2 202629 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CANbridge Pharmaceuticals Inc is a Chinese biopharmaceutical company focused on developing and commercializing treatments for rare diseases and cancer. The company engages in drug discovery, licensing, and clinical development, with a pipeline spanning gene therapy and biologics. It operates in both China and global markets through partnerships and R&D collaborations. The company is headquartered in Beijing, China, and its shares are listed on the HKEX.